만성 정신분열증 환자에서 Alprazolam의 치료 효과에 대한 이중맹 연구

• 영문명: A Double Blind Clinical Study on the Effects of Alprazolam on Chronic Schizophrenic Patients
• 발행기관: 대한신경정신의학회
• 저자명: 김광기 권영준 한선호
• 간행물 정보: 『신경정신의학』제33권 제1호, 240~248쪽, 전체 9쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 1994.01.30

영문 초록

Recently the treatment of intractable schizophrenia is the current concern of researchers. The purposes of this study were to investigate the efficacy of alprazolam as a neuroleptic adjunct for chronic schizophrenia. The subjects consisted of 46 inpatients who were diagnosed as schizophrenia based on DSM-III-R criteria. The subjects were randomly assigned to receive either alprazolam and neuroleptics, or placebo and neuroleptics. The maximum dosage of alprazolam was 4.5mg per day, and the duration of study was 6 weeks. Clinical evaluation with HAR S (Hamilton’s Anxiety Rating Scale) and BPRS (Brief Psychiatric Rating Scale) were done weekly on the double-blind method. The results of study showed that alprazolam produced significantly more clinical improvement than placebo in anxiety that included somatic concern, anergia subscale, and hostile-suspiciousness subscale. But BPRS total score, thought disturbance subscale, and activatation subscale showed no significant correlation between alprazolam-treated inpatient group and placebo-treated inpatient group. The side effects of alprazolam were not reported, except that the only one patient who received alprazolam, had side effect of daytime drowsiness

목차

서 론

연구대상 및 방법

연 구 결 과

고 찰

결 론

참 고 문 헌

키워드

Alprazolam Schizophrenia Brief psychiatric rating scale Hamilton’s An-xiety rating scale